Show results for
prostate-specific-membrane-antigen Downloads
4 downloads found
Prostate cancer is one of the leading causes of morbidity and mortality in men in the western world, and the second most common cancer in men worldwide. Imaging of the prostate-specific membrane antigen (PSMA) has become an essential tool for managing patients with recurrent prostate cancer and 68Ga PSMA-11 is one of the most frequently employed radiopharmaceuticals. ...
PLUVICTO is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based ...
LOCAMETZ, after radiolabeling with gallium-68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy, with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. for ...
Prostate Specific Antigen (PSA) is a single chain glycoprotein produced by epithelial cells of the prostate gland. PSA is useful in the management of patients with prostate cancer. The measurement of serum PSA has become the most accepted test to indicate men who are at risk of having prostate cancer and who should be examined by other tests. Using a cut-off of 4 ng/ml, 92% of men over 50 years ...